Ocugen Reports Third Quarter Revenue and EPS Beat
Ocugen, Inc. (OCGN) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.01, outperforming estimates by $0.05, while revenue reached $1.95 million, representing an 11.4% increase year-over-year and beating projections by $1.17 million. The market responded positively to the earnings beat, with shares rising approximately 6% in after-hours trading. Investors are closely monitoring upcoming clinical catalysts, particularly regarding OCU410ST and data related to Stargardt disease, which remain central to the company's long-term growth strategy.
Tickers: $OCGN
Topics: biotechnology earnings beat revenue growth